Authors:
Khuri, FR
Rigas, JR
Figlin, RA
Gralla, RJ
Shin, DM
Munden, R
Fox, N
Huyghe, MR
Kean, Y
Reich, SD
Hong, WK
Citation: Fr. Khuri et al., Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer, J CL ONCOL, 19(10), 2001, pp. 2626-2637
Citation: Pj. Hollen et al., Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS), SUPP CARE C, 7(3), 1999, pp. 140-148
Authors:
Gralla, RJ
Osoba, D
Kris, MG
Kirkbride, P
Hesketh, PJ
Chinnery, LW
Clark-Snow, R
Gill, DP
Groshen, S
Grunberg, S
Koeller, JM
Morrow, GR
Perez, EA
Silber, JH
Pfister, DG
Citation: Rj. Gralla et al., Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines, J CL ONCOL, 17(9), 1999, pp. 2971-2994
Authors:
Hesketh, PJ
Gralla, RJ
Webb, RT
Ueno, W
DelPrete, S
Bachinsky, ME
Dirlam, NL
Stack, CB
Silberman, SL
Citation: Pj. Hesketh et al., Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis, J CL ONCOL, 17(1), 1999, pp. 338-343
Authors:
Eckardt, JR
Green, MR
Gralla, RJ
Langer, CJ
Eastman, A
Socinski, MA
Citation: Jr. Eckardt et al., Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer - Discussion II, SEMIN ONCOL, 26(5), 1999, pp. 71-72
Authors:
Navari, RM
Reinhardt, RR
Gralla, RJ
Kris, MG
Hesketh, PJ
Khojasteh, A
Kindler, H
Grote, TH
Pendergrass, K
Grunberg, SM
Carides, AD
Gertz, BJ
Citation: Rm. Navari et al., Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptorantagonist, N ENG J MED, 340(3), 1999, pp. 190-195